Jcog9702
Web2 feb 2024 · A phase III trial (JCOG9702) of carboplatin and etoposide versus split cisplatin (cisplatin administered in divided doses) and etoposide in patients aged ≥70 (PS, 0‑2) and <70 (PS, 3) years showed more grade 3/4 thrombocytopenia in patients given carboplatin and etoposide (56 vs. 16%, respectively; http://www.jcog.jp/document/9702.htm
Jcog9702
Did you know?
WebIn patients unfit for cisplatin due to advanced age or poor performance status (PS), carboplatin plus etoposide (CE) is as effective as cisplatin plus etoposide (JCOG9702 … http://www.jcog.jp/document/s_9702.pdf
Web1 giu 2005 · In a previous study (JCOG9702), the ORR was 73%, median PFS was 5.2 months, and median OS was 10.6 months in patients with ES-SCLC aged <70 years and … Web15 lug 2004 · 7217 Background: Elderly patients (>=75 year-old) have a great risk for chemotherapy, however, appropriate chemotherapy has improved survival and QOL in patients (pts) with SCLC. The combination with cisplatin and VP-16 is an active regimen for SCLC, and CBDCA is an analogue of cisplatin with less nonhematological toxicity. Based …
Web17 ott 2024 · Another trial (JCOG9702) that compared CDDP+ETP and CBDCA+ETP did not indicate a large difference in the efficacy endpoint between the two arms (HRos 1.04, HRpfs 0.92, and ORrr 1.0), using CDDP+ETP as reference. 26 However, this trial recruited only elderly Japanese patients; therefore, it remains unclear whether the results can be … http://www.jcog.jp/document/s_9702.pdf
Web1 ott 2024 · In patients (pts) unfit for cisplatin due to advanced age or poor performance status (PS), carboplatin plus etoposide (CE) is as effective as cisplatin plus etoposide (JCOG9702 trial), although ...
Web1 lug 2005 · Request PDF On Jul 1, 2005, H. Kunitoh and others published O-155 Randomized phase III trial of carboplatin (Cb) or cisplatin (P) in combination with etoposide (E) in elderly or poor-risk ... ウイルスベクターワクチン 仕組みhttp://www.jcog.jp/document/9702.htm pagination tutorial javascriptWeb1 set 2007 · I ntroduction. Twenty-five years ago we were poised to cure small cell lung cancer (SCLC). We had devised a unique staging system, established the effectiveness of several chemotherapeutic agents and radiation therapy, and even discovered the central nervous system sanctuary, which would require distinct treatment. pagination vantWeb21 lug 2024 · 1. Introduction. Before the era of molecular-targeted agents and immune checkpoint inhibitors (ICIs) such as a programmed cell death protein 1 (PD-1) antibody, the age of eligibility of elderly patients with advanced non-small cell lung cancer (NSCLC) in phase III randomized trials was often defined as 65 or 70 years [], and only 30–50% of … ウイルスベクター 課題Web1 set 2014 · In patients (pts) unfit for cisplatin due to advanced age or poor performance status (PS), carboplatin plus etoposide (CE) is as effective as cisplatin plus etoposide (JCOG9702 trial), although ... pagination validationWeb17 ott 2024 · Another trial (JCOG9702) that compared CDDP+ETP and CBDCA+ETP did not indicate a large difference in the efficacy endpoint between the two arms (HRos 1.04, HRpfs 0.92, and ORrr 1.0), using CDDP+ETP as reference. 26 However, this trial recruited only elderly Japanese patients; therefore, it remains unclear whether the results can be … ウイルスベクター 培養pagination visualforce